Immunovia AB

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovias proprietary test platform called IMMrayTM. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique disease biomarker signature. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMrayTM PanCan-d, is undergoing clinical evaluation...

Pancreatic cancer,early diagnosis of cancer,cancer therapy monitoring,patient classification,blood-based tests,antibody microarray technology,serum biomarker signatures,and autoimmune diseases diagnosis,prognosis and therapy monitoring

Immunovia ab operates in the Biotechnology research industry.

Immunovia ab's revenue is < 1m

Immunovia ab has 11 - 50 employees.